Turmeric, a type of Curcuma domestica, is a traditional medicinal plant in Indonesia. It contains curcuminoids, essential oils, starches, and various minerals. Turmeric has pharmacological benefits like improving blood circulation, reducing inflammation, and acting as an antibacterial agent. Dyslipidemia, a lipid metabolism disorder, can be evaluated in vivo and in vitro. This study aims to investigate the effectiveness of the ethanol extract of turmeric (Curcuma longa) as an anti-dyslipidemia agent in male Wistar rats treated with Propylthiouracil. The study was experimental with Pre-test and Post-test group-only control designs, using male Wistar rats as subjects. It was implemented in January 2024 with samples determined using the Federer formula. The calculations indicate that a minimum of 4 male Wistar rats (Rattus norvegicus) is required per treatment group. The rats should weigh between 180 and 200 grams and be between 2 and 4 months old. Turmeric ethanol extract (Curcuma Longa) significantly improved lipid profiles, especially at higher doses, reducing total Cholesterol, triglycerides, and LDL while increasing HDL in groups II and III. This anti-dyslipidemia effect is attributed to turmeric phytochemicals, particularly polyphenolic compounds, regulating pro-inflammatory cell signaling and interacting with gut microbiota. The extract, rich in curcumin antioxidants, shows promise as a non-pharmacological therapy for dyslipidemia and antiatherosclerosis. Moreover, it reduced SGOT and SGPT levels significantly, suggesting protection against Non-Alcoholic Fatty Liver Disease (NAFLD). However, potential mild NAFLD in the turmeric extract group requires further investigation.